Yukiko Sagawa

642 total citations
16 papers, 527 citations indexed

About

Yukiko Sagawa is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Yukiko Sagawa has authored 16 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 7 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Yukiko Sagawa's work include Immunotherapy and Immune Responses (10 papers), T-cell and B-cell Immunology (6 papers) and Immune Cell Function and Interaction (6 papers). Yukiko Sagawa is often cited by papers focused on Immunotherapy and Immune Responses (10 papers), T-cell and B-cell Immunology (6 papers) and Immune Cell Function and Interaction (6 papers). Yukiko Sagawa collaborates with scholars based in Japan and United States. Yukiko Sagawa's co-authors include Sadamu Homma, Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Yoshiro Nakahara, Tsuneya Ohno, Gotaro Toda, Hiroshi Wakui, Kazuyoshi Kuwano and Hideo Komita and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Clinical & Experimental Immunology and Immunology.

In The Last Decade

Yukiko Sagawa

16 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yukiko Sagawa Japan	12	386	297	127	126	52	16	527
Houssein Abdul Sater United States	11	373 1.0×	298 1.0×	81 0.6×	122 1.0×	41 0.8×	33	513
Esdy Rozali Australia	6	374 1.0×	238 0.8×	134 1.1×	101 0.8×	40 0.8×	8	516
Hongyu Zhao China	7	339 0.9×	312 1.1×	91 0.7×	133 1.1×	63 1.2×	17	522
Dmitrij Ostroumov Germany	5	337 0.9×	294 1.0×	60 0.5×	137 1.1×	63 1.2×	6	526
Junya Ohtake Japan	10	296 0.8×	276 0.9×	54 0.4×	192 1.5×	68 1.3×	18	524
Lena Horvath Austria	8	281 0.7×	167 0.6×	134 1.1×	157 1.2×	92 1.8×	17	456
Vui Pham United States	5	275 0.7×	159 0.5×	75 0.6×	223 1.8×	67 1.3×	5	447
Ravindra Uppaluri United States	10	313 0.8×	390 1.3×	44 0.3×	159 1.3×	62 1.2×	25	590
Jeanne Galaine France	12	298 0.8×	303 1.0×	51 0.4×	158 1.3×	58 1.1×	28	512
Gabriel Abril-Rodríguez United States	7	242 0.6×	178 0.6×	71 0.6×	130 1.0×	48 0.9×	9	373

Countries citing papers authored by Yukiko Sagawa

Since Specialization

Citations

This map shows the geographic impact of Yukiko Sagawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yukiko Sagawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yukiko Sagawa more than expected).

Fields of papers citing papers by Yukiko Sagawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yukiko Sagawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yukiko Sagawa. The network helps show where Yukiko Sagawa may publish in the future.

Co-authorship network of co-authors of Yukiko Sagawa

This figure shows the co-authorship network connecting the top 25 collaborators of Yukiko Sagawa. A scholar is included among the top collaborators of Yukiko Sagawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yukiko Sagawa. Yukiko Sagawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Sagawa, Yukiko, Takashi Nishimura, Katsushi Amano, et al.. (2019). High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer. Oncology Reports. 18 indexed citations

Okuma, Yusuke, Hiroshi Wakui, Hirofumi Utsumi, et al.. (2018). Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer. Clinical Lung Cancer. 19(5). 410–417.e1. 115 indexed citations

Kamata, Yuko, Yukiko Sagawa, Kazumi Hayashi, et al.. (2018). Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Pancreatology. 19(1). 88–96. 11 indexed citations

Homma, Sadamu, et al.. (2017). Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. International Immunopharmacology. 54. 39–45. 13 indexed citations

Okuma, Yusuke, Yukio Hosomi, Yoshiro Nakahara, et al.. (2016). High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 104. 1–6. 147 indexed citations

Koido, Shigeo, Masaki Ito, Yukiko Sagawa, et al.. (2014). Vaccination with vascular progenitor cells derived from induced pluripotent stem cells elicits antitumor immunity targeting vascular and tumor cells. Cancer Immunology Immunotherapy. 63(5). 459–468. 6 indexed citations

Takahara, Akitaka, Shigeo Koido, Masaki Ito, et al.. (2011). Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunology Immunotherapy. 60(9). 1289–1297. 46 indexed citations

Nagasaki, Eijiro, Akitaka Takahara, Shigeo Koido, et al.. (2010). Combined Treatment With Dendritic Cells and 5-fluorouracil Elicits Augmented NK Cell-mediated Antitumor Activity Through the Tumor Necrosis Factor-α Pathway. Journal of Immunotherapy. 33(5). 467–474. 16 indexed citations

Ito, Masaki, Hideaki Suzuki, Yukiko Sagawa, & Sadamu Homma. (2010). The identification of a novel Paneth cell-associated antigen in a familial adenomatous polyposis mouse model. Biochemical and Biophysical Research Communications. 400(4). 548–553. 1 indexed citations

10.

Koido, Shigeo, Eiichi Hara, Sadamu Homma, et al.. (2010). Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions. Clinical Immunology. 135(3). 384–400. 13 indexed citations

11.

Homma, Sadamu, Shigeo Koido, Yukiko Sagawa, et al.. (2009). Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity. Clinical & Experimental Immunology. 156(2). 344–352. 3 indexed citations

12.

Koido, Shigeo, Sadamu Homma, Eiichi Hara, et al.. (2008). In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells. Journal of Translational Medicine. 6(1). 51–51. 16 indexed citations

13.

Homma, Sadamu, Yukiko Sagawa, Hideo Komita, et al.. (2007). Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation. Cancer Immunology Immunotherapy. 56(8). 1265–1274. 11 indexed citations

14.

Homma, Sadamu, Yukiko Sagawa, Masaki Ito, Tsuneya Ohno, & Gotaro Toda. (2006). Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clinical & Experimental Immunology. 144(1). 41–47. 39 indexed citations

15.

Homma, Sadamu, Hideo Komita, Yukiko Sagawa, Tsuneya Ohno, & Gotaro Toda. (2005). Antitumour activity mediated by CD4⁺ cytotoxic T lymphocytes against MHC class II‐negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin‐12. Immunology. 115(4). 451–461. 43 indexed citations

16.

Homma, Sadamu, Tetsuro Kikuchi, Kazuhiko Ochiai, et al.. (2005). Cancer immunotherapy by fusions of dendritic and tumour cells and rh‐IL‐12. European Journal of Clinical Investigation. 35(4). 279–286. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact